Status and phase
Conditions
Treatments
About
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
18 participants in 1 patient group
Loading...
Central trial contact
Hongying Lv
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal